Bambusa Therapeutics
PrivateLast Round
Series A
Extension
Nov 17, 2025
Est. Valuation
$555M
Total Funding Raised
$145M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Bambusa Therapeutics is a biotechnology company that develops bispecific antibodies for the treatment of immunological and inflammatory disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Bambusa Therapeutics Comparables
Compare Bambusa Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Attovia Therapeutics | 80% | |
| Belenos Biosciences Inc. | 74% | |
| Dualitas Therapeutics | 71% |
Bambusa Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Nov 17, 2025 | ||||
| Series A | Feb 14, 2025 | ||||
| Seed | Sep 9, 2024 | ||||
| Series A Extension | Nov 17, 2023 |
Bambusa Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series A, Series A Extension |
| Salvia | Series A, Series A Extension, Seed |
| Janus Henderson Group | Series A, Series A Extension |
| ADAR1 Capital Management | Series A, Series A Extension |
| RA Capital Management | Series A Extension, Series A |
| Kohlberg Kravis Roberts | Series A |
| 渶策资本 | Series A, Series A Extension, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 28, 2026
Monthly visitors increased 37% MoM.
- May 25, 2026
Grew 18% QoQ from 17 to 20 employees.
Recent news
Latest coverage and updates
- goes_publicOct 9, 2026
Bambusa Therapeutics, Inc. files for an initial public offering in Massachusetts on Oct 9th '26
- is_developingOct 7, 2026
Bambusa Therapeutics, Inc. is developing BBT001, a half-life-extended bispecific antibody targeting IL-4Rα and interleukin-31, for atopic dermatitis and chronic spontaneous urticaria.
- hiresOct 7, 2026
Bambusa Therapeutics, Inc. appoints Jonathan I. Lieber as chief financial officer on Oct 7th '26, bringing more than three decades of biotechnology finance and capital markets experience to support its clinical and preclinical development programs.
- hiresOct 7, 2026
Bambusa Therapeutics, Inc. names Jonathan I. Lieber chief financial officer as it advances its bispecific antibody pipeline for immunology and inflammation diseases.
Bambusa Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Bambusa Therapeutics's valuation, stock price, and market status.
Is Bambusa Therapeutics a public or private company?
Bambusa Therapeutics is a private company.
What is the current stock price of Bambusa Therapeutics?
Bambusa Therapeutics is a private company, so its shares have no public market price. Caplight tracks Bambusa Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Bambusa Therapeutics worth (valuation)?
Bambusa Therapeutics's valuation is estimated at $555.0M based on funding round data.
Can I buy Bambusa Therapeutics stock?
Bambusa Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Bambusa Therapeutics's last funding round?
Bambusa Therapeutics's most recent funding round was Series A Extension on November 17, 2025.
Who are the main investors in Bambusa Therapeutics?
Key investors in Bambusa Therapeutics include RA Capital Management, BVF Partners L.P..
Will Bambusa Therapeutics IPO soon?
No public IPO plans have been announced for Bambusa Therapeutics.
How can I track Bambusa Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Bambusa Therapeutics's shares on secondary markets.